Literature DB >> 21519255

Experimental models of multiple sclerosis.

Andrew R Pachner1.   

Abstract

PURPOSE OF REVIEW: Multiple sclerosis (MS) is a disease of the central nervous system of unknown cause. There are many medications available for the disease, but none are clearly effective in ameliorating its long-term disabling effects. MS is felt to be most likely either due to an aberrant immune response or a pathogen, or possibly a combination of the two, and the animal models available reflect these two possible pathogeneses. The hallmarks of the disease are demyelination, inflammation, axonal injury, and progressive disability. This review explores the experimental models of multiple sclerosis. RECENT
FINDINGS: There are a variety of forms of experimental allergic encephalomyelitis, the most commonly studied animal model of MS. Two viruses, Theiler's murine encephalomyelitis virus and murine hepatitis virus, are used to induce infectious models of the disease.
SUMMARY: The animal models have their advantages and disadvantages, but no model fully reproduces the spectrum of the human disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519255     DOI: 10.1097/WCO.0b013e328346c226

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  37 in total

Review 1.  Gender differences in autoimmunity associated with exposure to environmental factors.

Authors:  K Michael Pollard
Journal:  J Autoimmun       Date:  2011-12-03       Impact factor: 7.094

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

3.  Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis.

Authors:  Magdalena Janina Laska; Tomasz Brudek; Kari Konstantin Nissen; Tove Christensen; Anné Møller-Larsen; Thor Petersen; Bjørn Andersen Nexø
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Automated multi-objective calibration of biological agent-based simulations.

Authors:  Mark N Read; Kieran Alden; Louis M Rose; Jon Timmis
Journal:  J R Soc Interface       Date:  2016-09       Impact factor: 4.118

5.  Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Authors:  Francesca Gilli; Libin Li; Darlene B Royce; Krista D DiSano; Andrew R Pachner
Journal:  J Neurovirol       Date:  2017-09-14       Impact factor: 2.643

6.  Low-dose 5-aza-2'-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells.

Authors:  Michael W Y Chan; Chia-Bin Chang; Chien-Hsueh Tung; Justin Sun; Jau-Ling Suen; Shu-Fen Wu
Journal:  Mol Med       Date:  2014-06-26       Impact factor: 6.354

Review 7.  Vitamin D, multiple sclerosis and inflammatory bowel disease.

Authors:  Margherita T Cantorna
Journal:  Arch Biochem Biophys       Date:  2011-11-10       Impact factor: 4.013

Review 8.  Will the real multiple sclerosis please stand up?

Authors:  Peter K Stys; Gerald W Zamponi; Jan van Minnen; Jeroen J G Geurts
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

Review 9.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 10.  Regulation of oligodendrocyte precursor migration during development, in adulthood and in pathology.

Authors:  Fernando de Castro; Ana Bribián; Maria Cristina Ortega
Journal:  Cell Mol Life Sci       Date:  2013-05-21       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.